Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Elraglusib - Actuate Therapeutics

Next Previous
Drug Profile

Elraglusib - Actuate Therapeutics

Alternative Names: 9 ING 41

Latest Information Update: 08 Apr 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Northwestern University; University of Illinois at Chicago
  • Developer Actuate Therapeutics; Incyte Corporation
  • Class Antineoplastics; Benzofurans; Dioxolanes; Indoles; Pyrroles; Small molecules
  • Mechanism of Action Glycogen synthase kinase 3 beta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma; Pancreatic cancer; Soft tissue sarcoma; Neuroblastoma; Adenocarcinoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Adenoid cystic carcinoma; Myelofibrosis; Neuroblastoma; Pancreatic cancer; Salivary gland cancer
  • Phase I/II Cancer
  • Preclinical Brain cancer
  • No development reported Chronic lymphocytic leukaemia; Colorectal cancer

Most Recent Events

  • 06 Apr 2026 Actuate Therapeutics plans a phase II trial for Malignant melanoma (Metastatic disease, Second line therapy or greater) in first half of 2027 (PO, Tablet) (Actuate Therapeutics pipeline, April 2026)
  • 06 Apr 2026 Actuate Therapeutics plans a phase I Actuate-2601 trial for Solid tumours (Late-stage disease, Second line therapy or greater) in first half of 2026 (PO, Tablet) (Actuate Therapeutics pipeline, April 2026)
  • 06 Apr 2026 Actuate Therapeutics plans a phase II trial for Neuroblastoma (In children) in second half of 2026 (IV) (Actuate Therapeutics pipeline, April 2026)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top